View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDSM-Firmenich 配当と自社株買い配当金 基準チェック /16DSM-Firmenich配当を支払う会社であり、現在の利回りは0.79%です。主要情報0.8%配当利回り1.4%バイバック利回り総株主利回り2.2%将来の配当利回り2.2%配当成長1.4%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向-130%最近の配当と自社株買いの更新お知らせ • Feb 15DSM-Firmenich AG Proposes Dividend for the Financial Year 2023At the Annual General Meeting on May 7, 2024, dsm-firmenich's Board of Directors announced it will propose a cash dividend of €2.50 per share for the financial year 2023.お知らせ • Feb 18DSM Firmenich Announces Intention Pay Final Gross DividendDSM Firmenich announced intention to pay a gross dividend of EUR 423 million, which will be almost EUR 1.6 per share as a sort of final dividend.すべての更新を表示Recent updatesお知らせ • Oct 03Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich.Lesaffre et Compagnie, SA agreed to acquire Yeast Extract Business of DSM-Firmenich on June 3, 2024. Also as part of the deal, some of the dsm-firmenich employees working on Yeast Extracts will transfer to Lesaffre. The transaction is subject to customary regulatory approvals and works council consultations at dsm-firmenich and is expected to be closed by the end of 2024. Stephanie Horowitz, Hansuya Reddy, Floris van de Bult and Michiel Sunderman of Clifford Chance acted as legal advisor for DSM-Firmenich AG. Yeast Extract Business has an annual sales of about €120 million. Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich on October 2, 2024.お知らせ • Jul 31DSM-Firmenich AG to Report Fiscal Year 2024 Results on Feb 13, 2025DSM-Firmenich AG announced that they will report fiscal year 2024 results on Feb 13, 2025お知らせ • May 08+ 1 more updateDsm-Firmenich Ag Approves Retirement of Pradeep Pant from the BoardDSM-Firmenich AG announced that at its Annual General Meeting the board thanked Pradeep Pant for his distinguished service. Pradeep, who joined the board of DSM in 2016 and later served on the board, did not stand for re-election as he reached the statutory age limit.お知らせ • Mar 08Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR).Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR) on March 8, 2024.Jingjiang Cosfocus Health Technology Co., Ltd completed the acquisition of DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR) on March 8, 2024.お知らせ • Feb 15DSM-Firmenich AG Proposes Dividend for the Financial Year 2023At the Annual General Meeting on May 7, 2024, dsm-firmenich's Board of Directors announced it will propose a cash dividend of €2.50 per share for the financial year 2023.お知らせ • Jan 19DSM-Firmenich AG to Report First Half, 2024 Results on Jul 30, 2024DSM-Firmenich AG announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Jan 09DSM-Firmenich Makes Voluntary Cash Offer for DSM SharesDSM-Firmenich AG (ENXTAM:DSFIR) (the Company or dsm-firmenich) and Koninklijke DSM N.V. (DSM B.V.) (DSM) announced that the remaining holders of DSM ordinary shares will have the opportunity to sell their DSM ordinary shares to dsm-firmenich through the voluntary tender offer launched by dsm-firmenich January 8, 2024. The details of the tender offer are set out in this press release. Statutory Buy-Out: dsm-firmenich started a statutory buy-out procedure (the Buy-Out) on July 17, 2023 to acquire the remaining ordinary shares, about 3.9%, in DSM, previously Koninklijke DSM N.V. (the Shares). On such date, dsm-firmenich already held 96.1% of the Shares. For this Buy-Out, the Company has requested the Enterprise Chamber of the Amsterdam Court of Appeal (Ondernemingskamer) to set – in line with past practice – the fair price of the Shares at the closing share price of a dsm-firmenich ordinary share on Euronext Amsterdam on May 3, 2023. This price amounts to €116, minus the dividend paid on the Shares of €22.58 on July 3, 2023, and with any further dividends or other distributions yet to be paid on the Shares also to be deducted. This Buy-Out may extend well into 2024.お知らせ • Oct 31DSM-Firmenich AG, Annual General Meeting, May 07, 2024DSM-Firmenich AG, Annual General Meeting, May 07, 2024.お知らせ • Aug 03DSM-Firmenich AG to Report Fiscal Year 2023 Results on Feb 15, 2024DSM-Firmenich AG announced that they will report fiscal year 2023 results on Feb 15, 2024お知らせ • Feb 18DSM Firmenich Announces Intention Pay Final Gross DividendDSM Firmenich announced intention to pay a gross dividend of EUR 423 million, which will be almost EUR 1.6 per share as a sort of final dividend.お知らせ • Nov 01Koninklijke DSM N.V. to Report Fiscal Year 2022 Results on Feb 16, 2023Koninklijke DSM N.V. announced that they will report fiscal year 2022 results on Feb 16, 2023決済の安定と成長配当データの取得安定した配当: KDSK.Fは配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。増加する配当: KDSK.Fは配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。 配当利回り対市場DSM-Firmenich 配当利回り対市場KDSK.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (KDSK.F)0.8%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Chemicals)1.7%アナリスト予想 (KDSK.F) (最長3年)2.2%注目すべき配当: KDSK.Fの配当金 ( 0.79% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) と比べると目立ったものではありません。高配当: KDSK.Fの配当金 ( 0.79% ) はUS市場の配当金支払者の上位 25% ( 4.22% ) と比較すると低いです。株主への利益配当収益カバレッジ: KDSK.Fは配当金を支払っていますが、会社は利益を上げていません。株主配当金キャッシュフローカバレッジ: KDSK.Fの 現金配当性向 ( 33.2% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/20 04:50終値2024/08/20 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DSM-Firmenich AG 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40 アナリスト機関Jennifer BarkerBarclaysAlexander SloaneBarclaysSebastian BrayBerenberg37 その他のアナリストを表示
お知らせ • Feb 15DSM-Firmenich AG Proposes Dividend for the Financial Year 2023At the Annual General Meeting on May 7, 2024, dsm-firmenich's Board of Directors announced it will propose a cash dividend of €2.50 per share for the financial year 2023.
お知らせ • Feb 18DSM Firmenich Announces Intention Pay Final Gross DividendDSM Firmenich announced intention to pay a gross dividend of EUR 423 million, which will be almost EUR 1.6 per share as a sort of final dividend.
お知らせ • Oct 03Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich.Lesaffre et Compagnie, SA agreed to acquire Yeast Extract Business of DSM-Firmenich on June 3, 2024. Also as part of the deal, some of the dsm-firmenich employees working on Yeast Extracts will transfer to Lesaffre. The transaction is subject to customary regulatory approvals and works council consultations at dsm-firmenich and is expected to be closed by the end of 2024. Stephanie Horowitz, Hansuya Reddy, Floris van de Bult and Michiel Sunderman of Clifford Chance acted as legal advisor for DSM-Firmenich AG. Yeast Extract Business has an annual sales of about €120 million. Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich on October 2, 2024.
お知らせ • Jul 31DSM-Firmenich AG to Report Fiscal Year 2024 Results on Feb 13, 2025DSM-Firmenich AG announced that they will report fiscal year 2024 results on Feb 13, 2025
お知らせ • May 08+ 1 more updateDsm-Firmenich Ag Approves Retirement of Pradeep Pant from the BoardDSM-Firmenich AG announced that at its Annual General Meeting the board thanked Pradeep Pant for his distinguished service. Pradeep, who joined the board of DSM in 2016 and later served on the board, did not stand for re-election as he reached the statutory age limit.
お知らせ • Mar 08Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR).Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR) on March 8, 2024.Jingjiang Cosfocus Health Technology Co., Ltd completed the acquisition of DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR) on March 8, 2024.
お知らせ • Feb 15DSM-Firmenich AG Proposes Dividend for the Financial Year 2023At the Annual General Meeting on May 7, 2024, dsm-firmenich's Board of Directors announced it will propose a cash dividend of €2.50 per share for the financial year 2023.
お知らせ • Jan 19DSM-Firmenich AG to Report First Half, 2024 Results on Jul 30, 2024DSM-Firmenich AG announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Jan 09DSM-Firmenich Makes Voluntary Cash Offer for DSM SharesDSM-Firmenich AG (ENXTAM:DSFIR) (the Company or dsm-firmenich) and Koninklijke DSM N.V. (DSM B.V.) (DSM) announced that the remaining holders of DSM ordinary shares will have the opportunity to sell their DSM ordinary shares to dsm-firmenich through the voluntary tender offer launched by dsm-firmenich January 8, 2024. The details of the tender offer are set out in this press release. Statutory Buy-Out: dsm-firmenich started a statutory buy-out procedure (the Buy-Out) on July 17, 2023 to acquire the remaining ordinary shares, about 3.9%, in DSM, previously Koninklijke DSM N.V. (the Shares). On such date, dsm-firmenich already held 96.1% of the Shares. For this Buy-Out, the Company has requested the Enterprise Chamber of the Amsterdam Court of Appeal (Ondernemingskamer) to set – in line with past practice – the fair price of the Shares at the closing share price of a dsm-firmenich ordinary share on Euronext Amsterdam on May 3, 2023. This price amounts to €116, minus the dividend paid on the Shares of €22.58 on July 3, 2023, and with any further dividends or other distributions yet to be paid on the Shares also to be deducted. This Buy-Out may extend well into 2024.
お知らせ • Oct 31DSM-Firmenich AG, Annual General Meeting, May 07, 2024DSM-Firmenich AG, Annual General Meeting, May 07, 2024.
お知らせ • Aug 03DSM-Firmenich AG to Report Fiscal Year 2023 Results on Feb 15, 2024DSM-Firmenich AG announced that they will report fiscal year 2023 results on Feb 15, 2024
お知らせ • Feb 18DSM Firmenich Announces Intention Pay Final Gross DividendDSM Firmenich announced intention to pay a gross dividend of EUR 423 million, which will be almost EUR 1.6 per share as a sort of final dividend.
お知らせ • Nov 01Koninklijke DSM N.V. to Report Fiscal Year 2022 Results on Feb 16, 2023Koninklijke DSM N.V. announced that they will report fiscal year 2022 results on Feb 16, 2023